The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Phase II trial of a PARP inhibitor in somatic BRCA mutant metastatic breast cancer.
 
Neelima Vidula
Consulting or Advisory Role - Abbvie
Research Funding - DAEHWA Pharmaceutical (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Radius Health (Inst)
 
Nora K. Horick
No Relationships to Disclose
 
Erica Blouch
No Relationships to Disclose
 
Amalia Rivera
No Relationships to Disclose
 
Erin Basile
No Relationships to Disclose
 
Ruth Fax
No Relationships to Disclose
 
Leif W. Ellisen
Honoraria - Invitae
Travel, Accommodations, Expenses - Invitae
 
Hope S. Rugo
Consulting or Advisory Role - Celltrion; Ionis Pharmaceuticals
Research Funding - Daiichi Sankyo (Inst); Eisai (Inst); Genentech (Inst); Immunomedics (Inst); Lilly (Inst); Macrogenics (Inst); Merck (Inst); Novartis (Inst); OBI Pharma (Inst); Odonate Therapeutics (Inst); Pfizer (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Macrogenics; Merck; Mylan; Novartis; OBI Pharma; Pfizer; Puma Biotechnology
 
Aditya Bardia
Consulting or Advisory Role - bioTheranostics; Genentech; Genentech/Roche (Inst); Immunomedics; Immunomedics (Inst); Innocrin Pharma (Inst); Merck; Novartis; Novartis (Inst); Pfizer; Pfizer (Inst); Puma Biotechnology; Radius Health; Radius Health (Inst); Sanofi; Spectrum Pharmaceuticals
Research Funding - bioTheranostics